# 18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer.

> **NCT06335069** · PHASE2 · RECRUITING · sponsor: **Maastricht University Medical Center** · enrollment: 20 (estimated)

## Conditions studied

- Breast Cancer
- Breast Neoplasms
- Breast Diseases

## Interventions

- **DIAGNOSTIC_TEST:** 68Ga-FAPI-46 PET/CT and 68Ga-FAPI-46 PET/MRI

## Key facts

- **NCT ID:** NCT06335069
- **Lead sponsor:** Maastricht University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06335069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06335069, "18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06335069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*